Tratamento da HAP Idiopática, Hereditária ou Associada a Medicamentos em Doentes com Comorbilidades Cardiopulmonares
Este protocolo aborda o tratamento farmacológico de primeira linha para doentes com hipertensão arterial pulmonar idiopática (IPAH), hereditária (HPAH) ou associada a medicamentos (DPAH) que apresentam simultaneamente comorbilidades cardiopulmonares com sobreposição de fatores de risco para HFpEF.
References
Treatment decisions in patients with IPAH/HPAH/DPAH or PAH-CTD should be stratified according to the presence or absence of cardiopulmonary comorbidities (Section 6.3.4.3) and according to disease severity assessed by risk stratification (Section 6.2.7).
Cardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of hypertension, and/or a low DLCO.
In patients with IPAH/HPAH/DPAH and cardiopulmonary comorbidities, initial monotherapy with a PDE5i or an ERA should be considered.
Initial monotherapy is recommended for most of these patients, with PDE5is being the most widely used compounds according to registry data.
View source ↗